Cleo Diagnostics

Cleo Completes Design Transfer

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm that it has concluded design transfer activities relating to the core technology for its ovarian cancer detection test.


Highlights

  • Design transfer establishes Cleo’s capability to deliver reproducible and reliable results for its ovarian cancer detection test
  • Tender process for the selection of an antibody manufacturer in final stage
  • Technology transfer to commence by end of the calendar quarter
DESIGN TRANSFER

Cleo has completed the design transfer of the CXCL10 active ratio test into a more rigorous laboratory environment, ensuring the capability to deliver reproducible and reliable results. This advancement enhances the performance of the test, transitioning it from academic methodologies to a compliant and robust laboratory setting. The test will continue to progress through the development pathway, culminating in an FDA 510K application for regulatory approval.

As outlined in the clinical validation study publication (see ASX Announcement 6 November 2023), the CXCL10 active ratio measures changes in a key immune process to give an indication of the presence of a tumour, and is an important component of Cleo’s biomarker panel to be incorporated within its commercially available test kits.

Cleo’s first product to market will be a pre-surgical triage test, designed to determine the likelihood that a pre-surgical ovarian mass is either benign or malignant prior to referral for surgical intervention. The test will be used in conjunction with clinical and radiological evaluation of a patient by physicians, to improve the referral process and better inform clinical decision making workflows. Ovarian masses (typically benign cysts) are very common and non-life threatening; around 10% of women will have surgery during their lifetime for investigation of an ovarian mass, representing a significant market opportunity for Cleo’s first product.

The completion of design transfer forms the basis for Cleo to progress technology transfer to a manufacturer as the next step. The Company is currently finalising a tender process for the selection of an antibody manufacturer and expects it will be in a position to announce a partner by the end of the quarter, with completion of technology transfer to follow shortly thereafter.

Commenting on the completion of design transfer, Cleo Chief Scientific Officer, Dr Andrew Stephens, said:

“The confirmation of design transfer demonstrates that the Cleo core antibody reagents and methodologies are robust and suitably reliable for transfer to a third party manufacturer for commercial test-kit development.”


Click here for the full ASX Release

This article includes content from CLEO Diagnostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

COV:AU
Cleo Diagnostics

Cleo Diagnostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Cleo Diagnostics (ASX:COV)

Cleo Diagnostics


Keep reading...Show less

Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results

  • Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basis
  • Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic 1 basis
  • Full-Year revenue growth in Salix, International, Solta and Bausch + Lomb segments on both a Reported and Organic 1 basis
  • GAAP Net Loss Attributable to Bausch Health Companies Inc. of $39 million for the quarter and $592 million for the year
  • Adjusted EBITDA Attributable to Bausch Health Companies Inc. 1 of $869 million for the quarter, up 6%, and $3.0 billion for the year, in line with prior year

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth-quarter and full-year 2023 financial results

"I am pleased that we delivered against the financial guidance we established at the beginning of 2023. During the year, we made meaningful progress in driving performance across each of our business segments, continued to focus on our balance sheet and liquidity, and made significant progress on our key R&D initiatives, all helping to position the Company for continued growth and performance. We are excited about the positive momentum in our business as we enter 2024 and will continue to prioritize advancing our pipeline, investing in initiatives to continue to drive growth, and positioning the Company for long-term success," said Thomas J. Appio, Chief Executive Officer, Bausch Health.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Knight has previously submitted marketing authorization applications for fostamatinib in Colombia and Mexico.

"This submission of fostamatinib demonstrates Knight's continued execution of our strategy of leveraging our solid platform and expertise to bring innovative therapies for important unmet healthcare needs in Latin America," said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Upfront Tuition Coverage Is a Game-Changer for Medtronic Employees

MAPS program helped remove barriers to education; Candi Sneed becomes first link in a chain of future engineers

Candi Sneed had always been passionate about pursuing higher education and a career in engineering. However, the cost of tuition and the lack of flexibility in traditional academic programs have been a barrier for her. That was until she discovered the Medtronic Advancement Pathways and Skill-building (MAPS) program

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic reports third quarter fiscal 2024 financial results

Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth; Raises full year guidance

Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Medical Technology Stocks to Keep On The Radar

(NewsDirect)

The healthcare technology industry is one that offers investors a plethora of opportunities. With global healthcare spending soaring to approximately $8.3 trillion and nearly half of that amount allocated in the U.S. alone, the sector presents intriguing growth prospects. As the healthcare industry outpaces the overall global economy in growth, investors find themselves on the cusp of a promising market.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Making Earlier Detection of Ovarian Cancer a Reality

Corporate Presentation February 2024

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer, using its novel patented CXCL10 biomarker.

Keep reading...Show less
Cleo Diagnostics

Cleo Diagnostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×